{"id":2905,"date":"2021-03-11T13:34:27","date_gmt":"2021-03-11T12:34:27","guid":{"rendered":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/?p=2905"},"modified":"2021-03-11T13:34:27","modified_gmt":"2021-03-11T12:34:27","slug":"complemento-personal-2400-e","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/complemento-personal-2400-e\/","title":{"rendered":"Complemento personal 2400 \u20ac"},"content":{"rendered":"\n<p>Todos los trabajadores de GP 1, 2, 3 y 4 de Towa Pharmaceuticals, percibir\u00e1n como m\u00ednimo, un Complemento Personal de 2400\u20ac, que ser\u00e1 abonado a partir del mes en que cumplan 2 a\u00f1os de antig\u00fcedad como empleados de Towa.<\/p>\n\n\n\n<p>Para el c\u00f3mputo de la antig\u00fcedad, se tendr\u00e1 en cuenta el periodo de ETT, cuando haya sido de forma ininterrumpida e inmediatamente anterior a su incorporaci\u00f3n en plantilla Towa.<\/p>\n\n\n\n<p>Dicho complemento personal, tendr\u00e1 la misma naturaleza y ser\u00e1 adicional al 3% establecido en el pacto cuarto del acuerdo colectivo de fecha 30 de junio de 2015, por el que se establece el nuevo sistema de remuneraci\u00f3n.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Todos los trabajadores de GP 1, 2, 3 y 4 de Towa Pharmaceuticals, percibir\u00e1n como m\u00ednimo, un Complemento Personal de 2400\u20ac, que ser\u00e1 abonado a partir del mes en que &#8230; <a title=\"Complemento personal 2400 \u20ac\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/complemento-personal-2400-e\/\" aria-label=\"Leer m\u00e1s sobre Complemento personal 2400 \u20ac\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2905","post","type-post","status-publish","format-standard","hentry","category-blog","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/2905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=2905"}],"version-history":[{"count":1,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/2905\/revisions"}],"predecessor-version":[{"id":2906,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/2905\/revisions\/2906"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=2905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=2905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=2905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}